Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiopharma Cred. Share News (BPCR)

Share Price Information for Biopharma Cred. (BPCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.844
Bid: 0.834
Ask: 0.844
Change: 0.00 (0.00%)
Spread: 0.01 (1.199%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.844
BPCR Live PriceLast checked at -
BioPharma Credit is an Investment Trust

To generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SUMMARY: London listings with exposure to Silicon Valley Bank

Mon, 13th Mar 2023 12:18

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

FTSE 250

----------

Syncona Ltd - London-based investor in healthcare companies - Says it has cash and cash equivalents with SVB UK Ltd equating less than 0.4% of its capital base of GBP653.8 million, and 0.2% of its net asset value. Portfolio companies have "range of banking relationships" including SVB and SVB UK, and estimates its indirect exposure across portfolio is around 6% of NAV, "with all but a de minimus amount with SVBUK". Working closely with portfolio companies to support ongoing operations, and engagement with SVBUK and other parties to recovery deposits. Has strong capital base to support portfolio companies if required, awaits guidance from Bank of England over progress and timeline to potentially recover deposits.

----------

IP Group PLC - Oxford, England-based intellectual property commercialisation company - Confirms no direct deposits, credit facilities or other relationships with SVB or SVB UK. Boasts strong balance sheet, with GBP241.5 million in gross cash and deposits as at December 31, and total potential liquidity of over GBP500 million. Working closely with "small number" of portfolio companies that may require short-term liquidity. "Our strong financial position means we are well placed to support our portfolio," firm says.

----------

Auction Technology Group PLC - London-based online auction operator - Says SVB is involved in its senior facilities arrangement with syndicate of six banks. The arrangement consists of a fully-drawn USD150.3 million senior term loan, and a USD49.0 million multi-currency revolving credit facility, which is drawn down by USD24.3 million. SVB represents one sixth of its respective drawn and undrawn facilities. Says liquidity position strong, benefitting from operational cash generation and access to liquidity from other five banks in syndicate. As at Thursday, has USD10.0 million cash at bank, with 5% held on deposit at SVB. "This deposit is held across the group's different US entities. The group uses JP Morgan Chase and HSBC for its main clearing and operational uses," firm says. Expects "no material impact" to current or future liquidity from SVB situation.

----------

Moonpig Group PLC - online greeting card and gifting company - Says SVB is one of ten lenders in banking syndicate which provide its senior debt facilities. Has "significant" liquidity headroom, including utilised and available facilities of GBP242 million, which are committed until December 8 2025. "This excludes the GBP13 million undrawn portion of SVB UK's commitment," firm says. Confirms no cash on deposit with SVB UK and no bank account held with them.

----------

Apax Global Alpha Ltd - Guernsey-based closed-ended investment company - Receives update from Apax Partners, which advises certain private equity funds in which it is a limited partner. Says review is ongoing but exposure to SVB "appears to be limited". Review has not identified any portfolio company with funded debt or revolvers placed with SVB. Small number of portfolio companies have bank accounts at SVB, but the "vast majority of which only hold a very limited amount of cash". No exposure to SVB at the level of Apax Funds.

----------

Future PLC - Bath, England-based magazine publisher - Says cash deposits with SVB were less than 3% of its cash on hand as at Thursday. SVB also provided GBP50 million of its GBP900 million total debt facilities. "Of this GBP50 million, approximately 48% is currently drawn," it says. Has access to "significant" liquidity, with GBP26 million cash on hand as at Friday, and GBP438 million of undrawn committed facilities, excluding SVB's undrawn hold.

----------

HgCapital Trust PLC - London-based investment firm - Says "little to no impact" on the firm from SVB collapse. Says neither Hg, nor any of its managed funds, have related loan or borrowing exposure with SVB. None of its underlying portfolio companies have outstanding borrowings with SVB. "A small number of the underlying portfolio companies have limited deposits with SVB, but no portfolio business is at risk as a result of this."

----------

LARGE SMALL-CAP AND AIM LISTINGS

----------

Team17 Group PLC - Nottingham, England-based video game development company and publisher of educational entertainment apps for children - Says Team17 USA, part of its Games Label division has legacy banking relationship with SVB, but the account is "no longer used for current trading". Says exposure to SVB is less than 1% of cash reserves at present, and "as such is immaterial to the group's liquidity position".

----------

Learning Technologies Group PLC - London-based learning and talent solutions - Says exposure to SVB and SVB UK does not have "material effect" on financial position. As at Friday, had total cash and cash equivalents of GBP110.7 million, of which around GBP11.7 million was on deposit with SVB and SVB UK. Around GBP9.4 million was with SVB, with around GBP2.3 million with SVB UK. Requested withdrawal of deposits, and has received GBP300,000 to date. "The company will continue to pursue any unreturned deposits, including if necessary through the relevant receivership process," LTG says. SVB was also part of its banking syndicate, which comprises HSBC, Bank of Ireland, and Fifth Third Bank. The facilities comprise a drawn USD255.4 million loan - with SVB providing USD53.7 million, and an undrawn revolving credit facility of USD50 million - with SVB's share being USD10.5 million. "SVB's portion of the term loan will continue to be outstanding until it is due to be repaid or SVB is replaced." Says it's unlikely SVB will fund any future drawings on RCF, but the remaining USD39.5 million will be available as normal. SVB was also facility agent for the lending syndicate, and the firm will find a replacement.

----------

THG PLC - Manchester Airport-headquartered e-commerce retail company - Confirms no exposure to SVB in relation to cash or debt facilities.

----------

RWS Holdings PLC - Buckinghamshire, England-based technology-enabled language services provider - Says exposure to SBV "limited", with SVB UK being part of its eight-bank syndicated providing USD220 million revolving credit facility, having committed around 10% of the facility. Around USD26 million is currently drawn down, of which SVB's share is USD2.7 million. Has "small" cash position held within SVB in the US, which it believes with be fully protected under the Federal Deposit Insurance Corporation scheme. SVB UK holds "a portion" of its forward currency contracts, and RWS is working to minimise its "limited" exposure to these contracts. Reiterates outlook from annual general meeting statement, expecting to delivery annual adjusted pretax profit in line with market expectations.

----------

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell therapy group - Says its US facility maintains a checking and deposit account with SVB. Has no accounts with SVB UK. "Oxford Biomedica confirms it has no balance sheet risk exposure to the SVB receivership issue."

----------

Alpha Group International PLC - London-based provider of financial solutions - Says operations and client held funds unaffected by SVB situations. Reaffirms that all client funds are in segregated safeguarding accounts with tier 1 counterparties, comprised of Barclays Bank, Citibank, Goldman Sachs, and Lloyds Bank. "In addition, unlike a bank, Alpha does not use client cash to issue loans, and therefore 100% of client held funds remain in cash at all times," it explains. Says it will monitor potential knock-on effects from SVB on its clients.

----------

BioPharma Credit PLC - Winchester, England-based life sciences debt investment trust - The firm's investment adviser, Pharmakon Advisors, says firm does not hold deposits or other investments in SVB. Has consulted the firm's borrowers, and they report "no significant exposure" to SVB.

----------

OTHER

----------

Dianomi PLC - London-based digital advertising platform - Says on Thursday's close of business, it had total cash balances of around GBP9.6 million, mostly held with JPMorgan and Westpac, but around GBP3.8 million was held with SVB and SVB UK "across a variety of different currency accounts". They held GBP900,000 and GBP2.9 million respectively. Noting developments in the UK and US, now expects these deposits to be fully protected.

----------

Trustpilot Group PLC - Copenhagen-based online consumer reviews platform - Says SVB UK was principal banking partner. Its immediately accessible cash is USD24 million, made up of USD19 million cash on deposit with another bank, USD4.5 million guaranteed by the US Federal Reserve after Sunday's announcement, and amounts due to be returned under guaranteed deposit insurance schemes in UK. "The board is confident in Trustpilot's' liquidity position and resilience. Meanwhile, we have put in place measures to proactively manage our cash position during this period of uncertainty, and wider unpredictability in the current macroeconomic environment," Trustpilot says.

----------

Polarean Imaging PLC - London-based medical imaging technology company - Says at the end of February it had USD13.9 million in cash, with USD12.4 million held at SVB. USD9.8 million of the amount held by SVB is held in money market mutual fund accounts operated by other financial institutions. Also holds USD1.0 million in SVB checking account, and GBP1.2 million in SVB sterling checking account. Notes FDIC guarantees USD250,000 of deposits in US. Believes USD9.8m MMFA shares are not considered deposits of SVB, and therefore are not part of the receivership estate. "However, Polarean may not have immediate access to these funds until the FDIC establishes procedures for access," the firm says. Says USD1.5 million held by Wells Fargo will fund its working capital needs until the end of April this year.

----------

Diaceutics PLC - Belfast-based testing laboratories company - Says as at Thursday, it holds GBP19.8 million in cash and cash equivalents with SVB UK. Is now confident the funds will be fully recovered, following HSBC acquisition. Earlier, the firm had ordered the suspension of its shares on AIM, due to uncertainty about its ability to service working capital requirements. It now removes suspension. Continues trying to get access to the GBP2.2 million held on deposit with SVB in the US. Following the announcement from the Federal Reserve about restoring access to deposits, it expects to be able to access the funds in the "near term".

----------

Naked Wines PLC - Norwich-based online wine seller - Says holds cash in variety of SVB accounts in US and UK. SVB is also administrative agent and issuing lender for its USD60 million asset-backed credit facility. On Friday, had gross cash on hand of GBP32 million, GBP14 million of which was held in cash sweep account with SVB acting as custodian for third party money market funds. Believes it is entitled to return of these funds in full, after completing any procedures required by FDIC. Is uncertain of the time frame in which it will gain full access to these funds. Says day-to-day operations unaffected, and doesn't expect to incur any loss as a result. Says GBP17 million available in immediately accessible cash.

----------

Access Intelligence PLC - London-based software-as-a-service products provider - Says SVB it has deposits with less than GBP400,000 held across a number of SVB accounts in the UK and US. It expects most of the funds, if not all, to be protected by the UK Financial Services Compensation Scheme and the US FDIC. "However the exact timing of when these funds might be available to the company still remains uncertain," firm says. Notes SVB is not a banking partner of the company in the Asia-Pacific region.

----------

Glantus Holdings PLC - Dublin-based data platform for accounts payable and shared services - Says it SVB is used for US operations. "Proactively managing" situation, and does not expected significant operational difficulties. Says maximum exposure will "only slightly" exceed the USD250,000 amount insured by FDIC. "Consequently, the board is confident that the current situation regarding SVB will not have a material impact on Glantus."

----------

Medica Group PLC - Hastings, England-based company which provides services such as X-ray and MRI scan analysis to hospitals - Says SVB UK is part of three-bank lending consortium, alongside NatWest and Lloyds. Says around GBP10 million of the GBP30 million revolving credit facility was being used at the end of December. "The RCF facility is not required for day-to-day activity, is not forecast to be further drawn and Medica intends to pay this facility down out of trading cashflows within the next 12-18 months," firm says. Has no cash on deposit nor conducts any day-to-day commercial banking with any SVB entity.

----------

eEnergy Group PLC - London-based energy efficiency-as-a-service provider - Says it has no material operating cash exposure to SVB, but maintains a number of bank accounts with SVB UK, "primarily used in relation to collections from clients on behalf of project funders". Its primary relationship with SVB concerns currency hedging, and a fully drawn GBP5 million revolving credit facility. "The board does not expect any material impact to its business, adjusted earnings or cash position."

----------

Venture Life Group PLC - Berkshire, England-based self-care product manufacturer and distributor - Says SVB participates in its GBP30 million revolving credit facility, which is primarily co-ordinated and managed by firm's main relationship bank, Santander UK. SVB provides 50% of the funds drawn under the facility. The RCF has an option for Santander to take of SVB's portion, or for another lender to participate in the RCF. "The group has commenced discussions with Santander in relation to Santander doing this, and those initial discussions have been positive," VLG says. Santander and firm will accelerate plans to refinance the RCF, given that it expires next June. Says firm and subsidiaries have no deposits with SVB in UK or US, meaning no funds at risk.

----------

Checkit PLC - Cambridge-based workflow management software provider - Says exposure to SVB less than GBP100,000. Says balance sheet strong, with net cash of GBP15.6 million at January 31.

----------

PCI-PAL PLC - Global cloud provider of secure payment solutions for business communications - As of Thursday, had GBP3.2 million of cash in accounts with SVB, split between the US and UK. Notes US and UK developments ensuring safety of its deposits. Says trading in the second so far has been in line with the board's expectations.

----------

Yourgene Health PLC - Manchester-based molecular diagnostics - Says it has GBP3 million in outstanding borrowings under a loan agreement with SVB UK. Holds around GBP20,000 on deposit with SVB UK in accounts which are only used to pay loan instalments or associated interest. Says SVB US exposure is for day-to-day trading purposes for small US commercial team, and "handful" of company credit cards. Says the "modest" level of funds held in US SVB account were transferred to other banks last week. Believes remaining SVB deposits are protected by relevant insurance schemes in UK and US.

----------

musicMagpie PLC - Stockport, England-based used-technology reseller - Says it had a loan arrangement with SVB, but this ended when it entered the three-year GBP30 million revolving credit facility with HSBC and NatWest last July. Its US trading brand, decluttr, uses SVB for day-to-day activities. Says SVB closure in US is unlikely to impact business because decluttr can use alternative banking relationships. "The group had already been in discussions to move its US transactional banking relationship away from SVB," the firm says.

----------

Windward Ltd - Liverpool, England-based maritime predictive intelligence company - Says exposure "minimal", and expects funds to be protected by US and UK schemes. Says exposure amount is less than 0.5% of its cash position, which was USD22.2 million at December 31.

----------

Eagle Eye Solutions Group PLC - London-based marketing solutions provider - Says it has a GBP5.0 million loan facility with SVB UK, which is draw down by GBP2.0 million. On Friday, had total cash of around GBP7.8 million. Notes some funds deposited with SVB in US, but expects these to be protected and available from today. Has no cash deposits with SVB UK.

----------

GetBusy PLC - Cambridge, England-based document management and productivity software provider - Says its previous loan facility with SVB was cancelled last month, and replaced with a GBP2 million facility with DJZ Investments Pty Ltd. "Following this executed change, the group has no exposure to SVB for any loan facilities." Says no exposure to uninsured deposits with SVB, given the announcements from the Treasure, Federal Reserve and FDIC on Sunday.

----------

The following firms cited no banking relationship with/no exposure to SVB:

Argentex Group PLC

Avacta Group PLC

Cornerstone FS PLC

CyanConnode Holdings PLC

Equals Group PLC

Evgen Pharma PLC

Fiinu PLC

GENinCode PLC

Instem PLC

LungLife AI Inc

Mercia Asset Management PLC

Renalytix PLC

Roquefort Therapeutics PLC

Scancell Holdings PLC

Science Group PLC

Seeing Machines Ltd

Spectral MD Holdings Ltd

Tern PLC

Verici Dx PLC

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
21 Nov 2022 11:21

BioPharma Credit agrees loan agreement with subsidiary for Immunocore

(Alliance News) - BioPharma Credit PLC said on Monday it has entered into a definitive senior secured loan agreement with its fully-owned subsidiary BioPharma Credit Investments V Master LP for Immunocore Ltd.

Read more
20 Oct 2022 14:00

BioPharma makes investment in Insmed for disease therapy development

(Alliance News) - BioPharma Credit PLC on Thursday said it has made a USD140.0 million investment in US biopharmaceutical company Insmed Inc for the development of therapies to treat neutrophil-mediated inflammatory diseases and rare pulmonary disorders.

Read more
13 Oct 2022 12:26

IN BRIEF: BioPharma Credit pays special dividend; NAV increases

BioPharma Credit PLC - Winchester, England-based life sciences debt investment trust - Declares an interim dividend of USD0.0625 for its third quarter ended September 30. This comprises of a special dividend of USD0.0450 and an ordinary dividend of USD0.0175. Says it is on track to pay and continues to target a 7 cent base annual dividend.

Read more
6 Oct 2022 12:59

IN BRIEF: BioPharma Credit receives USD175 million from Pfizer deal

Biopharma Credit PLC - New York-based life sciences debt investment trust - Company's investment manager, Pharmakon Advisors, notes the announcement made by Pfizer Inc on Wednesday about acquisition of Global Blood Therapeutics for USD5.4 billion. BioPharma had USD132.5 million investment in Global Blood Therapeutics in a senior secured loan which has been prepaid following the acquisition. The senior secured loan was invested through three different tranches. In total the company received USD175.4 million, including USD42.9 million of accrued interest, paydown, prepayment and make-whole fees, realising an internal rate of return of 28%.

Read more
14 Sep 2022 10:42

BioPharma Credit net asset value and half-year profit both rise

(Alliance News) - BioPharma Credit PLC on Wednesday posted a slightly higher net asset value as profit shot up on the back of increased investment.

Read more
7 Sep 2022 15:53

UK earnings, trading statements calendar - next 7 days

Thursday 8 September 
Arecor Therapeutics PLCHalf Year Results
Cairn Homes PLCHalf Year Results
Chaarat Gold Holdings LtdHalf Year Results
Curtis Banks Group PLCHalf Year Results
Darktrace PLCFull Year Results
Destiny Pharma Holdings PLCHalf Year Results
Duke Royalty LtdFull Year Results
Emis Group PLCHalf Year Results
Energean PLCHalf Year Results
Funding Circle Holdings PLCHalf Year Results
Genus PLCFull Year Results
International Public Partnerships LtdHalf Year Results
Melrose Industries PLCHalf Year Results
Mpac Group PLCHalf Year Results
M Winkworth PLCHalf Year Results
Oakley Capital Investments LtdHalf Year Results
Open Orphan PLCHalf Year Results
Restaurant Group PLCHalf Year Results
Safestore Holdings PLCQ3 Results
Severfield PLCFull Year Results
Shield Therapeutics PLCHalf Year Results
SourceBio International PLCHalf Year Results
Spire Healthcare Group PLCHalf Year Results
Sylvania Platinum LtdFull Year Results
Vistry Group PLCHalf Year Results
Friday 9 September 
Computacenter PLCHalf Year Results
Creo Medical Group PLCHalf Year Results
Mid Wynd International Investment Trust PLCFull Year Results
Monday 12 September 
ABCAM PLCHalf Year Results
Arcontech Group PLCFull Year Results
Associated British Foods PLCFull Year Results
Greencoat Renewables PLCHalf Year Results
HgCapital Trust PLCHalf Year Results
Kape Technologies PLCHalf Year Results
Made Tech Group PLCFull Year Results
MP Evans Group PLCHalf Year Results
SigmaRoc PLCHalf Year Results
Tirupati Graphite PLCFull Year Results
Tuesday 13 September 
accesso Technology Group PLCHalf Year Results
Churchill China PLCHalf Year Results
Corero Network Security PLCHalf Year Results
Engage XR Holdings PLCHalf Year Results
Facilities by ADF PLCHalf Year Results
Fevertree Drinks PLCHalf Year Results
Futura Medical PLCHalf Year Results
Gateley Holdings PLCFull Year Results
Harworth Group PLCHalf Year Results
HeiQ PLCHalf Year Results
JTC PLCHalf Year Results
Mattioli Woods PLCFull Year Results
Ocado Group PLCTrading Statement
Oxford Nanopore Technologies PLCHalf Year Results
Petra Diamonds LtdFull Year Results
Property Franchise Group PLCHalf Year Results
RBG Holdings PLCHalf Year Results
Smart Metering Systems PLCHalf Year Results
Team17 Group PLCHalf Year Results
Trustpilot Group PLCHalf Year Results
VH Global Sustainable Energy Opportunities PLCHalf Year Results
Wednesday 14 September 
Anpario PLCHalf Year Results
Advanced Medical Solutions Group PLCHalf Year Results
BioPharma Credit PLCHalf Year Results
Blackbird PLCHalf Year Results
Central Asia Metals PLCHalf Year Results
Diurnal Group PLCHalf Year Results
Dunelm Group PLCFull Year Results
Epwin Group PLCHalf Year Results
Glenveagh Properties PLCHalf Year Results
ITM Power PLCFull Year Results
Niox Group PLCHalf Year Results
Pan African Resources PLCFull Year Results
Pharos Energy PLCHalf Year Results
Redrow PLCFull Year Results
Ricardo PLCFull Year Results
STM Group PLCHalf Year Results
Artisanal Spirits Co PLCHalf Year Results
Tullow Oil PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
22 Aug 2022 19:00

IN BRIEF: BioPharma Credit says Epizyme investment repaid amid buyout

BioPharma Credit PLC - life sciences debt investment trust - Says had USD110 million investment in Epizyme Inc in form of senior secured loan. "The loan was made in four different tranches and each tranche had different prepayment economics," BioPharma adds. Ipsen on Friday completed acquisition of biopharmaceutical firm Epizyme. BioPharma says has received USD119 million, including USD9 million prepayment and make-whole fees. Realises internal rate of return of just over 15%.

Read more
9 Aug 2022 09:53

IN BRIEF: BioPharma Credit may benefit as Pfizer buys investee GBT

BioPharma Credit PLC - life sciences debt investment trust - Says it has USD132.5 million investment in Global Blood Therapeutics Inc, a company which has agreed to be acquired by Pfizer Inc. BioPharma investment is in form of senior secured loan. Loan will be prepaid when Pfizer buy of GBT closes. "The loan was invested in three different tranches with each tranche subject to different prepayment economics," BioPharma adds. Should prepayment occur before start of October, BioPharma will receive US38 million through paydown, prepayment and make-whole fees.

Read more
20 Jul 2022 13:51

IN BRIEF: BioPharma revises loan agreements with Akebia Therapeutics

BioPharma Credit PLC - Winchester, England-based life sciences debt investment trust - Says that together with BioPharma Credit Investments V it has entered into a second amendment and waiver with Akebia Therapeutics Inc. This amends and waives certain provisions of the USD100 million loan agreement dated November 11, 2019. As a result of this amendment Akebia has made a USD25 million prepayment, reducing the outstanding balance to USD75 million. Akebia will make payments on the remaining balance as originally agreed, starting in September. The loan balance is expected to be USD27 million by January 2024.

Read more
28 Jun 2022 20:17

IN BRIEF: BioPharma Credit says Epizyme investment to be prepaid

BioPharma Credit PLC - life sciences debt investment trust - Notes Monday's announcement from Ipsen regarding its agreement to acquire Epizyme Inc. BioPharma has a USD110 million investment in a senior secured loan in Epizyme, which it says would be prepaid upon closing of the acquisition. "The loan was made in four different tranches with each tranche having a different prepayment economics. Depending on the actual timing of the prepayment, the company would be expected to receive between USD3 million to USD7 million in prepayment and make-whole fees," company explains.

Read more
6 Jun 2022 15:58

UK shareholder meetings calendar - next 7 days

Tuesday 7 June  
Animalcare Group PLCAGM
Arix Bioscience PLCAGM
Centrica PLCAGM
Integrated Diagnostics Holdings PLCAGM
Kooth PLCAGM
Ondine Biomedical IncAGM
Osirium Technologies PLCAGM
SpaceandPeople PLCAGM
TruFin PLCAGM
Wednesday 8 June  
Ascent Resources PLCAGM
Cambridge Cognition Holdings PLCAGM
City Pub Group PLCAGM
DP Eurasia NVAGM
Gem Diamonds LtdAGM
Hiro Metaverse Acquisitions I SAAGM
Itaconix PLCAGM
M&G Credit Income Investment Trust PLCAGM
Nostrum Oil & Gas PLCAGM
Parity Group PLCAGM
Petards Group PLCAGM
Safestyle UK PLCAGM
Savannah Resources PLCAGM
Third Point Investors LtdAGM
Woodbois LtdAGM
Thursday 9 June 
4basebio PLCAGM
Northbridge Industrial Services PLCGM re name change to Crestchic
Funding Circle Holdings PLCAGM
Northbridge Industrial Services PLCAGM
Dignity PLCAGM
Corero Network Security PLCAGM
Kosmos Energy PLCAGM
Kistos PLCAGM
Tungsten Corp PLCGM re Kofax Offer
BioPharma Credit PLCAGM
Checkit PLCAGM
Panther Metals PLCAGM
Instem PLCAGM
Kore Potash PLCAGM
Rambler Metals & Mining PLCAGM
Xpediator PLCAGM
Round Hill Music Royalty Fund LtdAGM
REA Holdings PLCAGM
Invesco Perpetual UK Smaller Companies Investment Trust PLCAGM
BlackRock Smaller Companies Trust PLCAGM
Friday 10 June 
Chariot LtdAGM
MP Evans Group PLCAGM
THG PLCAGM
Ergomed PLCAGM
Ultra Electronics Holdings PLCAGM
XLMedia PLCAGM
Monday 13 June 
Angus Energy PLCGM re second tranche of subscription shares and warrants
Elixirr International PLCAGM
Ocean Outdoor LtdGM re takeover by Atairos Group Inc
Jupiter Emerging & Frontier Income Trust PLCGM re voluntary liquidation
Mirriad Advertising PLCAGM
Saga PLCAGM
Spectra Systems CorpAGM
VPC Speciality Lending Investments PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
22 Apr 2022 06:57

IN BRIEF: Investment manager completes sale of BioPharma Credit shares

BioPharma Credit PLC - life sciences debt investment trust - Pablo Legorreta, co-founder of Pharmakon Advisors, the company's investment manager, completes sale of 55.0 million shares in BioPharma, a 4.0% stake. The disposal, run by JP Morgan Cazenove, was at USD0.97 per share, so worth USD53.4 million. Legorreta, who also is founder & chief executive officer of Royalty Pharma, retains 21.7 million shares, a 1.6% stake. BioPharma Credit receives no proceeds, as the sale is of existing shares.

Read more
20 Apr 2022 15:58

IN BRIEF: BioPharma Credit investment manager in USD56 million sale

BioPharma Credit PLC - life sciences debt investment trust - Pablo Legorreta, co-founder of Pharmakon Advisors, the company's investment manager, will sell 55.0 million shares in BioPharma, a 4.0% stake. The sale will be conducted immediately by JP Morgan Cazenove as an accelerated book building process to institutional investors. At the current market price, the sale would be worth about USD56 million. Legorreta, who also is founder & chief executive officer of Royalty Pharma, will retain 21.7 million shares, a 1.6% stake. BioPharma Credit will receive no proceeds, as the sale is of existing shares.

Read more
22 Mar 2022 21:01

EARNINGS UPDATES: MP Evans dividend outlook bright; ScS share buyback

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.